PMID- 29577044
OWN - NLM
STAT- MEDLINE
DCOM- 20181002
LR  - 20220408
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2018
DP  - 2018
TI  - Tubulointerstitial Biomarkers for Diabetic Nephropathy.
PG  - 2852398
LID - 10.1155/2018/2852398 [doi]
LID - 2852398
AB  - Patients with diabetic nephropathy have a higher risk of mortality, mostly from 
      cardiovascular complications. Standard biomarkers including serum creatinine, 
      estimated glomerular filtration rate, and albuminuria are imprecise, do not 
      directly measure renal tissue injury, and are relatively insensitive to small 
      changes in renal function. Thus, availability of novel biomarkers that are 
      sensitive, specific, and precise as well as able to detect kidney injury and 
      predict clinically significant outcomes would be widely useful in diabetic 
      nephropathy. Novel biomarkers of the processes that induce tubulointerstitial 
      changes may ultimately prove to better predict renal progression and prognosis in 
      type 2 diabetes. Recently, certain biomarkers, which were initially identified in 
      acute kidney injury, also have been reported to confer value in evaluating 
      patients with chronic kidney disease. Biomarkers such as cystatin C, kidney 
      injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), 
      angiotensinogen, periostin, and monocyte chemoattractant protein-1 (MCP-1) 
      reflect tubular injury. In this article, we focused on the potential applications 
      of these biomarkers in diabetic nephropathy.
FAU - Satirapoj, Bancha
AU  - Satirapoj B
AUID- ORCID: 0000-0002-8881-0942
AD  - Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and 
      College of Medicine, Bangkok, Thailand.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180208
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cystatin C)
RN  - 0 (HAVCR1 protein, human)
RN  - 0 (Hepatitis A Virus Cellular Receptor 1)
RN  - 0 (Lipocalin-2)
RN  - 11002-13-4 (Angiotensinogen)
SB  - IM
MH  - Angiotensinogen/blood
MH  - Biomarkers/*blood
MH  - Chemokine CCL2/blood
MH  - Cystatin C/blood
MH  - Diabetic Nephropathies/blood/*diagnosis
MH  - Hepatitis A Virus Cellular Receptor 1/blood
MH  - Humans
MH  - Lipocalin-2/blood
PMC - PMC5822931
EDAT- 2018/03/27 06:00
MHDA- 2018/10/03 06:00
PMCR- 2018/02/08
CRDT- 2018/03/27 06:00
PHST- 2017/10/26 00:00 [received]
PHST- 2017/12/29 00:00 [revised]
PHST- 2018/01/04 00:00 [accepted]
PHST- 2018/03/27 06:00 [entrez]
PHST- 2018/03/27 06:00 [pubmed]
PHST- 2018/10/03 06:00 [medline]
PHST- 2018/02/08 00:00 [pmc-release]
AID - 10.1155/2018/2852398 [doi]
PST - epublish
SO  - J Diabetes Res. 2018 Feb 8;2018:2852398. doi: 10.1155/2018/2852398. eCollection 
      2018.